Analysis of CSF AD core biomarkers revealed a higher proportion of A+ [amyloid-beta (Aß) positive] and T+ (phospho-tau positive) cases in the DLB and PDD groups than in the PD, MSA, and, to a lesser extent, PSP/CBS groups (Table 4), which correlated with lower MMSE scores in the former groups (Table 1). The gene discussed is MAPT; the disease is supranuclear palsy, progressive, 1.